Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weider

This article was originally published in The Tan Sheet

Executive Summary

Firm's Schiff Move Free joint supplement sales fell 2.9% in the first quarter versus the prior year period which is "unacceptable, but does indicate we are starting to stabilize the brand," CEO Bruce Wood comments in Sept. 25 earnings call. In March, Weider implemented a brand-building initiative for Move Free that included over $12 mil. in ad spending to spur its sales (1"The Tan Sheet" Aug. 18, 2003, p. 13). Wood expects low, single-digit Move Free growth in Weider's 2004 fiscal year, driven by double-digit growth at year-end. The exec also says Weider plans to launch new products "branching into new broad human condition areas, an example being cardiovascular health," in 2005...

You may also be interested in...



Weider Move Free Advertising Strategy Key To Earnings Improvement

Weider says a recently launched brand-building initiative for its Schiff division's Move Free joint supplement product line will help return the company to positive earnings in the coming year

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel